Core Insights - BioPorto A/S announced its annual financial results for 2025, confirming preliminary figures released earlier in February 2026 [1][2]. Financial Performance - Total revenue for FY 2025 reached DKK 40.3 million, reflecting an 11% increase from FY 2024 and a 13% increase at constant exchange rates (CER), aligning with the guidance of DKK 40-45 million [3][4]. - Total NGAL revenue increased to DKK 28.2 million, marking a 22% growth year-over-year and a 25% increase at CER [3][4]. - US NGAL revenue from Research Use Only (RUO) rose by 25% to DKK 18.4 million, with a 29% increase at CER [3][4]. - Adjusted EBITDA loss for 2025 was DKK 76.5 million, an 8% increase compared to 2024, within the guidance range of DKK 75-80 million [3][4]. - Cash and cash equivalents decreased to DKK 54.9 million from DKK 59.7 million in 2024, representing an 8% decline [3][4]. Strategic Developments - The company successfully secured commercial availability of ProNephro AKI (NGAL) for the US market through its distributor [5]. - A three-year "Forward" Strategic Plan was established in November 2025, focusing on market adoption and expansion towards 2028 [5]. - BioPorto executed a Financing Strategy with private placements totaling DKK 76.5 million in April and November 2025 [5]. - Patient enrollment for the ProNephro AKI (NGAL) study for adult use was completed by the end of October 2025, with plans to submit a pre-submission meeting request to the FDA in March 2026 [5]. Future Guidance - Guidance for FY 2026 remains unchanged, with total revenue expected to be between DKK 48-58 million, representing a 20-45% increase [6]. - Total NGAL revenue for FY 2026 is projected to be between DKK 33-42 million, indicating a 20-50% growth [6]. - Adjusted EBITDA loss for FY 2026 is anticipated to be between DKK 50-60 million, a decrease of 22-35% [6]. - The company aims for revenue between DKK 150-200 million by FY 2028, with an adjusted EBITDA margin of at least 15% [6].